VBL Therapeutics Climbs on Brain Cancer Results
Insights - VBL Therapeutics (VBLT) claimed success in a trial of lead drug candidate VB-111 in brain cancer on Wednesday, sending the stock higher by 40% in early trading.
Read NowInsights
More Details Emerge on Medivation’s XTANDI in Prostate Cancer
Insights - The data were presented at the 2015 European Association of Urology Congress.
Read Now
MEI Pharma’s Pracinostat Fails Latest Trial
Insights - A combination of MEI Pharma’s (MEIP) Pracinostat and the chemotherapy Vidaza (azacitidine) failed to improve remission rates compared to azacitidine alone in patients with Myelodysplastic Syndrome (MDS), … Continue Reading
Read Now
Biogen Idec Meets Investor Expectations with Early Alzheimer’s Drug
Insights - Even after adding $30 billion in market value over the last four months, shares of Biogen Idec (BIIB) moved higher on Friday morning with the release of … Continue Reading
Read Now
Retrophin’s Busy Week: A Financing, a Drug Approval and a Valuable FDA Voucher
Insights - Just a day after Retrophin (RTRX) announced a $100 million financing the U.S. FDA has approved its Cholbam (cholic acid) for pediatric and adult patients with bile … Continue Reading
Read Now
Esperion‘s Oral Cholesterol Drug Passes Latest Hurdle
Insights - Esperion Therapeutics, Inc. (ESPR) on released positive Phase 2b results for ETC-1002, its novel, oral cholesterol lowering therapy.
Read Now
Valeant Raises All-Cash Offer for Salix as Endo Bows Out
Insights - Valeant Pharmaceuticals (VRX) agreed to raise their outstanding offer for Salix Pharmaceuticals (SLXP) to $173/share in cash, from a $158 bid announced on January 16th, after Endo International … Continue Reading
Read Now